Resolutely focused on science
01
Our Mission
Exert Therapeutics is a rare disease company built to translate high-quality science into regulatory-ready medicines. Led by industry experts, we identify and advance therapeutic programmes where biological rationale, clinical feasibility and regulatory strategy are aligned from the outset.
Pioneering science to transform lives
02
Our Motivation
Exert focuses on rare and underserved conditions with significant unmet need and clear regulatory pathways.
Exert was founded to address a common failure mode in rare disease drug development: strong science paired with unrealistic development strategies.
Witnessing the determination of those affected by rare diseases drives us to want to make a difference.
Inspired by their courage
Mucopolysaccharidoses (MPS) explained
Mucopolysaccharidoses (type I to VII) are caused by the lack of an enzyme due to a genetic defect.
These enzymes are needed to break down glycosaminoglycans (GAGs), which build up in the cells and damage them.
Devastating diseases leading to a reduced life expectancy and very poor quality of life.
Find out more about MPS:
03
Our Science
We advance carefully selected therapeutic programmes with strong biological rationale and regulator-credible development strategies.
Determined to make a difference
PROGRAM 1
The lead program has demonstrated promising Phase IIa clinical proof-of-concept data in mucopolysaccharidosis type VI (MPS VI) and holds the potential to address other MPS subtypes.
PROGRAM 2
Our second program is a novel discovery-stage therapy for MPS III with a unique mechanism of action.
PORTFOLIO STRATEGY
Exert operates a selective portfolio model focused on late-preclinical and early clinical rare disease assets, evaluated against stringent scientific, clinical and regulatory criteria.
INVESTOR OPPORTUNITY
Exert builds regulatory-first development plans designed to create clear value inflection points for strategic partners and investors.
05
Contact Us
Ready to Partner with Us?
Contact us today.
David Boothe
Co-founder and CEO
David is a rare disease executive with over two decades of experience spanning clinical development, regulatory strategy, commercialisation and global launches of orphan medicines.
GSK | BioMarin | Spark | Shire | Orion
William Hariri
Co-founder and CBO
William has 12 years of Corporate Development experience with senior management positions in investment banks and in a clinical stage biotech as CBO. He has led numerous successful transactions.
Alira Health | Locust Walk | Enterome
Dr Aidan Gill
Medical Advisor
UK-registered Physician with 20+ years in Rare Diseases, spanning all phases of drug development globally. Expertise from clinical trial to strategic leadership.
Shire | PTC | Roche | Takeda
John Watson
Regulatory Advisor
John has 40+ years of experience in regulatory affairs, having led the approval of numerous rare disease and paediatric drugs.
Pharmion | NPS | ViroPharma | Zogenix | Biogen
Dr Tony Clarke
Drug Development Advisor
Tony has extensive leadership experience in R&D and has led multiple companies through acquisitions and global development efforts.
Brabant | Huxley | Amarin | Alexa | Zogenix
Dr Philippe Monteyne
Strategic Advisor
Partner at Aliath Bioventures, is a seasoned life sciences investor and former GSK and Sanofi executive. A neurologist with a PhD, he led the development of key treatments like Cervarix and Strimvelis. He serves on biotech boards across Europe and teaches in Brussels.
Exert Therapeutics – advancing rare disease medicines through regulatory-first development
05
Investment opportunity
01
Late-stage opportunity
Late-stage opportunity with near term value inflection points (phase IIb and III readout, regulatory filing, approval within 3 to 4 years)
02
Multidisciplinary team
Multidisciplinary team with expertise in rare disease and the ability to execute the development strategy and business plan
03
Clear value
We have a clear value proposition, clinical development plan and targets a defined patient population with high unmet medical needs
04
Business plan
Strong business case in MPS VI (~$500M market) and other MPS subtypes ($1B+)
05
Flexible strategy
Flexible exit scenarios, plan to establish a fully integrated commercial rare disease player, with potential for earlier exit at near term inflection points
04
Our Team
Multidisciplinary team with expertise in rare disease and the ability to execute the development strategy and business plan